Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]
In development [GID-TA10159] Expected publication date: TBC
Search results
693 results
-
-
Lenalidomide for untreated follicular lymphoma ID1245
In development [GID-TA10308] Expected publication date: TBC
-
Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467
In development [GID-TA10353] Expected publication date: TBC
-
Constipation (opioid induced) - methylnaltrexone bromide [ID700]
In development [GID-TA10003] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]
In development [GID-TA10008] Expected publication date: TBC
-
Reducing the mortality and morbidity for healthcare associated infections
In development [GID-NG10059] Expected publication date: TBC
-
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]
In development [GID-TA10236] Expected publication date: TBC
-
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]
In development [GID-TA10028] Expected publication date: TBC
-
Hernia
In development [GID-CGWAVE0771] Expected publication date: TBC
-
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487
In development [GID-TA10437] Expected publication date: TBC
-
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997
In development [GID-TA10382] Expected publication date: TBC
-
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]
In development [GID-TA10338] Expected publication date: TBC
-
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
In development [GID-TA10151] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492
In development [GID-TA10441] Expected publication date: TBC
-
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]
In development [GID-TA10154] Expected publication date: TBC
-
Renal cell carcinoma - sunitinib [ID1076]
In development [GID-TA10166] Expected publication date: TBC
-
Osteoarthritis - diacerein [ID332]
In development [GID-TAG250] Expected publication date: TBC
-
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172
In development [GID-TA10394] Expected publication date: TBC
-
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
In development [GID-TA10446] Expected publication date: TBC
-
Avelumab for previously treated platinum-resistant ovarian cancer ID1497
In development [GID-TA10404] Expected publication date: TBC
-
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]
In development [GID-TA10445] Expected publication date: TBC
-
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)
In development [GID-TA10337] Expected publication date: 19 February 2020
-
Pacritinib for treating myelofibrosis [ID880]
In development [GID-TA10133] Expected publication date: TBC
-
Atherothrombotic events - vorapaxar [ID616]
In development [GID-TAG493] Expected publication date: TBC
-
Head and neck cancer - intensity modulated radiotherapy [ID15]
In development [GID-TAG397] Expected publication date: TBC
-
Glaucoma - lerdelimumab (CAT-152) [ID383]
In development [GID-TAG381] Expected publication date: TBC
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Breast cancer (brain metastases) - etirinotecan pegol [ID881]
In development [GID-TA10066] Expected publication date: TBC
-
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
In development [GID-TA10375] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]
In development [GID-TA10693] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: TBC
-
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: 17 November 2021
-
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]
In development [GID-TA10387] Expected publication date: TBC
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Proposed [GID-TA10768] Expected publication date: TBC
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
-
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Midostaurin for treating advanced systemic mastocytosis ID1573
In development [GID-TA10503] Expected publication date: TBC
-
Postnatal care
In development [GID-NG10070] Expected publication date: 07 April 2021
-
Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury
In development [GID-NG10181] Expected publication date: TBC
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]
In development [GID-TA10209] Expected publication date: TBC